Učitavanje...
Glycaemic and non‐glycaemic efficacy of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
WHAT IS KNOWN AND OBJECTIVE: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) may confer a range of benefits for people with type 2 diabetes (T2D), which is reflected through their position within diabetes treatment guidelines. The objective of this narrative review is to explore the efficacy d...
Spremljeno u:
| Izdano u: | J Clin Pharm Ther |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540306/ https://ncbi.nlm.nih.gov/pubmed/32910489 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcpt.13224 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|